Breaking News
Get 40% Off 0
👀 Reveal Warren Buffett's stock picks that are beating the S&P 500 by +174.3% Get 40% Off

Citi sets $90 target for Biomea Fusion shares, sees over 800% upside

Published Nov 28, 2023 23:48
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters.
 
BMEA
-5.35%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
XBI
-3.08%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Biotech company Biomea Fusion has caught the attention of Wall Street after Citi, in a note released on Nov. 22, issued a Buy rating and set a remarkable $90 share price target, indicating around 800% upside. This optimistic forecast is based on the potential of Biomea's covalent therapies, including its promising BMF-219 diabetes treatment, which could reach $1.9 billion in U.S. sales by 2035.

Despite the inherent risks associated with biotech volatility and the uncertainty of clinical trials, Biomea's stock has shown resilience with an approximate 18% increase year-to-date (YTD). This bullish sentiment is echoed by FactSet, which shows a consensus analyst rating that forecasts a 385% upside. Oppenheimer is even more optimistic, projecting an upside of over 600%.

BMO (TSX:BMO) Capital Markets has suggested that biotech stocks have substantial growth prospects, especially if interest rates stabilize or decline. This economic environment could particularly benefit companies within the XBI ETF, which includes firms like Biomea Fusion.

InvestingPro Insights

As investors navigate the potential of Biomea Fusion's innovative therapies, it's vital to consider the company's financial health and market performance. According to InvestingPro, Biomea Fusion holds a significant advantage with more cash than debt on its balance sheet, providing a level of financial stability that is crucial in the high-stakes biotech sector. This aligns with the company's strategic positioning, as it continues to develop its BMF-219 diabetes treatment.

InvestingPro Data also reveals a market capitalization of $354.92M, which, while modest, reflects the growth potential that analysts see in the company. However, the P/E Ratio stands at -3.02, indicating that Biomea is not currently profitable, a common scenario for many biotech firms in their developmental stages. Additionally, the company's stock price has experienced a significant decline over the last six months, with a 68.28% drop, underscoring the volatility inherent in the biotech industry.

InvestingPro Tips suggest that four analysts have revised their earnings upwards for the upcoming period, demonstrating a growing confidence in Biomea's business prospects. Yet, it's important to note that the company is quickly burning through cash and suffers from weak gross profit margins. For investors looking for more comprehensive analysis, there are 12 additional InvestingPro Tips available, offering deeper insights into Biomea Fusion's financial and market performance.

For those considering an investment in Biomea or seeking to expand their biotech portfolio, InvestingPro subscription is now on a special Cyber Monday sale, with discounts of up to 55%. Use coupon code sfy23 to get an additional 10% off a 2-year InvestingPro+ subscription and gain access to valuable insights that could inform your investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Citi sets $90 target for Biomea Fusion shares, sees over 800% upside
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email